已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Sustained Efficacy and Safety in Adult and Pediatric Patients with Transfusion-Dependent β-Thalassemia up to 9 Years Post Treatment with Betibeglogene Autotemcel (Beti-cel)

地中海贫血 医学 输血 儿科 内科学
作者
Mark C. Walters,Alexis A. Thompson,Timothy S. Olson,John B. Porter,Jennifer Schneiderman,Suradej Hongeng,Andreas E. Kulozik,Marina Cavazzana,Martin G. Sauer,Adrian J. Thrasher,Isabelle Thuret,Ashutosh Lal,John E.J. Rasko,Evangelia Yannaki,Shamshad Ali,Ge Tao,Himal L. Thakar,Ami A. Deora,Katiana Gruppioni,Richard A. Colvin,Franco Locatelli,Janet L. Kwiatkowski
标识
DOI:10.1016/j.jtct.2023.12.301
摘要

Beti-cel gene therapy addresses the underlying cause of transfusion-dependent β-thalassemia (TDT) via autologous transplantation of hematopoietic stem and progenitor cells transduced with a functional version of the β-globin gene to produce normal adult hemoglobin (Hb), HbAT87Q. Here, we report long-term outcomes from patients treated with beti-cel. Patients with TDT who completed either a phase 1/2 (HGB-204 [NCT01745120]; HGB-205 [NCT02151526]) or phase 3 (HGB-207 [NCT02906202]; HGB-212 [NCT03207009]) beti-cel parent study and subsequently participated in the long-term, 13-year follow-up study LTF-303 (NCT02633943) were included. Efficacy (including transfusion independence [TI], defined as a weighted average Hb ≥9 g/dL without packed red blood cell transfusions for ≥12 months) and safety are reported through last follow-up. Key outcomes were also examined based on patient age at enrollment (pediatric: <18 years; adult: ≥18 years). As of January 30, 2023, 63 patients (median [range] age: 17 [4-35] years) had received beti-cel and enrolled in LTF-303, with a median (range) follow-up of 60.1 (23.8-109.5) months. In phase 3 studies, which used the commercial drug product (DP) manufacturing process, 37/41 (90.2%) patients achieved and maintained TI through last follow-up (up to 6 years; Table). In phase 1/2 studies that used an older DP manufacturing process, 15/22 (68.2%) patients achieved TI, and 14/15 sustained TI through last follow-up (up to 9 years). One patient no longer meets protocol-defined TI as a result of Hb level <9g/dL at year 6 due to acute health events unrelated to β-thalassemia, which were not attributed to loss of beti-cel treatment effect. Among all 63 patients, ≈80% of pediatric and adult patients required only 1 mobilization cycle to achieve the DP dose. Median percentage of transduced DP cells was comparable between adult and pediatric populations (78% and 80%, respectively), as were month 6 median peripheral blood vector copy number (1.4 c/dg and 1.1 c/dg) and HbAT87Q (9.4 g/dL and 8.3 g/dL). Overall, 12/63 (19.0%) patients experienced ≥1 beti-cel–related adverse event (AE); beti-cel–related AEs occurring in ≥3 patients included abdominal pain (5/63 [7.9%]) and thrombocytopenia (3/63 [4.8%]). Five patients experienced serious veno-occlusive liver disease; all 5 received defibrotide and recovered. No malignancies, insertional oncogenesis, or vector-derived replication-competent lentivirus were reported. Beti-cel is a potentially curative gene therapy for patients with TDT across ages and genotypes through achievement of TI and normal or near-normal Hb. These data will inform real-world beti-cel treatment decisions for patients with TDT.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CC发布了新的文献求助20
刚刚
超帅从彤完成签到 ,获得积分10
1秒前
桃桃发布了新的文献求助10
1秒前
斯文墨镜完成签到,获得积分20
2秒前
Nayvue完成签到,获得积分10
2秒前
3秒前
4秒前
Nayvue发布了新的文献求助10
7秒前
Unicorn完成签到,获得积分10
9秒前
研友_8K2QJZ完成签到,获得积分10
10秒前
10秒前
科研达人发布了新的文献求助10
10秒前
丝竹丛中墨未干完成签到,获得积分10
11秒前
包容的奇异果完成签到,获得积分10
14秒前
WHY完成签到 ,获得积分10
14秒前
娜娜子完成签到 ,获得积分10
15秒前
雪生在无人荒野完成签到,获得积分10
15秒前
完美世界应助桃桃采纳,获得10
16秒前
经年发布了新的文献求助10
17秒前
18秒前
tdtk发布了新的文献求助10
22秒前
22秒前
上官若男应助研友_Zlx3aZ采纳,获得10
22秒前
畅快沁完成签到,获得积分10
23秒前
ewmmel完成签到 ,获得积分10
23秒前
Rondab应助科研通管家采纳,获得10
26秒前
李爱国应助科研通管家采纳,获得10
26秒前
Rondab应助科研通管家采纳,获得10
26秒前
Rondab应助科研通管家采纳,获得20
26秒前
Rondab应助科研通管家采纳,获得10
26秒前
26秒前
27秒前
Rondab应助科研通管家采纳,获得10
27秒前
仰山雪完成签到 ,获得积分10
27秒前
霜鸣发布了新的文献求助10
27秒前
就看最后一篇完成签到 ,获得积分10
28秒前
29秒前
桃桃完成签到,获得积分10
30秒前
西瓜刀完成签到 ,获得积分10
32秒前
5Hepburn完成签到,获得积分20
33秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989957
求助须知:如何正确求助?哪些是违规求助? 3532034
关于积分的说明 11256000
捐赠科研通 3270880
什么是DOI,文献DOI怎么找? 1805070
邀请新用户注册赠送积分活动 882252
科研通“疑难数据库(出版商)”最低求助积分说明 809216